Introduction：Basic information about CAS 258818-34-7|Larazotide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Larazotide |
|---|
| CAS Number | 258818-34-7 | Molecular Weight | 725.83300 |
|---|
| Density | 1.254 | Boiling Point | / |
|---|
| Molecular Formula | C32H55N9O10 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid |
|---|
| Synonym | More Synonyms |
|---|
Larazotide BiologicalActivity
| Description | Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection[1][2]. |
|---|
| Related Catalog | Research Areas >>InfectionResearch Areas >>Inflammation/ImmunologySignaling Pathways >>Cytoskeleton >>Gap Junction Protein |
|---|
| In Vitro | Larazotide (1-100 μM; 5 d) affects Vero cell growth[1]. Larazotide (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively[1]. Larazotide (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells[2]. Larazotide (100 μM; 3 h) inhibits gliadin translocation across Caco-2 monolayers[2]. Larazotide (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells[2]. Cell Cytotoxicity Assay[1] Cell Line: Vero cell line Concentration: 1-100 μM Incubation Time: 5 days Result: Inhibited Vero cell growth with an CC50 value of 82.5 μM. |
|---|
| In Vivo | Larazotide (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice[1]. Animal Model: HLA-HCD4/DQ8 double transgenic mice[2] Dosage: 250 μg Administration: Intraperitoneal injection; 250 μg twice a week for 7 weeks Result: Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels. |
|---|
Chemical & Physical Properties
| Density | 1.254 |
|---|
| Molecular Formula | C32H55N9O10 |
|---|
| Molecular Weight | 725.83300 |
|---|
| Exact Mass | 725.40700 |
|---|
| PSA | 301.32000 |
|---|
| LogP | 0.49980 |
|---|
| InChIKey | ORFLZNAGUTZRLQ-ZMBVWFSWSA-N |
|---|
| SMILES | CC(C)CC(NC(=O)C(NC(=O)CNC(=O)CN)C(C)C)C(=O)NC(C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(=O)NCC(=O)O)C(C)C |
|---|
Synonyms
| UNII-ZN3R5560ZV |
| AT-2347 |
| Larazotide |
